Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary SinusReportar como inadecuado

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Chemotherapy Research and PracticeVolume 2014 2014, Article ID 487872, 6 pages

Clinical Study

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, India

Department of Head & Neck Surgery, Tata Memorial Hospital, Mumbai, India

Received 25 November 2013; Revised 23 March 2014; Accepted 3 April 2014; Published 11 May 2014

Academic Editor: Enzo Bonmassar

Copyright © 2014 Vanita Noronha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Locally advanced carcinoma of maxillary sinus has been historically reported to have poor prognosis. We evaluated the role of NACT in improving the outcome in these patients. Methods. 41 patients with locally advanced technically unresectable stage IVa or unresectable maxillary carcinoma stage IVb were treated with induction chemotherapy between 2008 and 2011. The demographic profile, response and toxicity of chemotherapy, definitive treatment received, progression free survival PFS, and overall survival OS were analyzed. Univariate and multivariate analysis were performed to determine factors associated with PFS and OS. Results. The chemotherapy included two drugs platinum and taxane in 34 patients 82.9% and three drugs platinum, taxane, and 5 FU in 7 17.1%. There was no complete response seen in any of the patients, stable disease in 18 43.9%, partial response in 16 39%, and progression in 7 17.1% patients. After induction, the treatment planned included surgery in 12 29.3%, CT-RT in 24 58.5%, radical RT in 1 2.4%, palliative RT in 1 2.4%, and palliative chemotherapy in 3 7.3% patients. Overall, the median PFS was 10.0 months. The OS at 24 months and 36 months was 41% and 35%, respectively. Conclusion. In unresectable maxillary carcinoma, induction chemotherapy has clinically significant benefit with acceptable toxicity.

Autor: Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Muddu Vamshi Krishna, Sachin Dhumal, Shashikant Juvekar, P. Pai, Pankaj Cha



Documentos relacionados